Post-treatment with the PPAR-γ agonist pioglitazone inhibits inflammation and bacterial growth during Klebsiella pneumonia

Agonists of peroxisome proliferator-activated receptor (PPAR)-γ have been suggested as potential adjuvant therapy in bacterial pneumonia because of their capacity to inhibit inflammation and enhance bacterial clearance. Previous studies only assessed the effects of pretreatment with these compounds,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramirez-Moral, Ivan, Ferreira, Bianca Lima, de Vos, Alex F., van der Poll, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375046/
https://www.ncbi.nlm.nih.gov/pubmed/34412637
http://dx.doi.org/10.1186/s12931-021-01823-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375046/
https://www.ncbi.nlm.nih.gov/pubmed/34412637
http://dx.doi.org/10.1186/s12931-021-01823-8

Ejemplares similares